We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva Pharmaceutical Industries Ltd. issued the following statement regarding the outstanding 1.5% Convertible Senior Notes due 2025 of Ivax Corporation, in connection with Teva's pending acquisition of Ivax.
The state-controlled Kenya Medical Supplies Agency (KEMSA), which is the sole provider of drugs to public hospitals in the country, is to change its distribution structure.
According to local media reports, Chile's government is coming under intense diplomatic pressure from the US and Switzerland to enforce data protection rules.
The cost of hospital care in China has recently come to the foreground after a patient in the country was charged CNY5.5mn (US$0.68mn) for two months of cancer treatment prior to his death.
CryoCath Technologies Inc., the global leader in cryotherapy products to treat cardiovascular disease, today announced financial results for the fourth quarter and fiscal year-ended September 30, 2005.
BioAlliance Pharma SA launched an IPO on Eurolist Compartment C of the Euronext stock exchange in Paris with the aim of raising ⁈29.5 to ⁈33.8 million and, in the words of its chairman and co-founder, Dominique Costantini, of "transmuting from a drug discovery company into a profitable pharmaceutical company.
Novartis (NOVN.VX: Quote, Profile, Research) has signed a cancer drug deal worth up to $520 million with private British biotech firm Astex Therapeutics, underlining the Swiss group's determination to build its presence in oncology.
Cephalon Inc. (CEPH.O: Quote, Profile, Research) has agreed to buy privately held Zeneus Holdings Ltd, parent of European biotech firm Zeneus Pharma, for about $360 million in cash in a bid to accelerate its drive into the European cancer market.